Caribou Biosciences, Inc. (CRBU): R&D Expense
$109.44M
Year ended 2025-12-31
$85.77M
Trailing 12 months to 2026-06-30
+10.0%
3-year compound annual growth
+26.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $109.44M | -15.9% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $130.15M | +16.1% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $112.08M | +36.3% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $82.23M | +57.4% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $52.26M | +51.8% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $34.42M | +45.7% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $23.64M | n/a | 2022-03-21, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $86.40M | +30.9% |
| Curis Inc (CRIS) | 2025-12-31 | $28.25M | -26.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $261.38M | -18.1% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
Compare CRBU, TCRX, ACOG, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗